Abstract: In one embodiment, the disclosure provides a computer-implemented method comprising: generating a unique identifier associated with a digital electronic workspace, a project, a first account, and a second account; receiving, from the first account, input granting permissions to a second account; generating initial requirements data; receiving, a second input indicating a first set of one or more of the digital requirement objects to associate with the unique identifier; receiving, from the second account, a third input to generate and digitally store an additional digital requirement object and associating that object with the unique identifier; receiving input indicating consensus that the project should possess all the features described in natural language text summaries represented by the digital requirement objects; and changing a state value of a variable associated with the unique identifier to a new state and displaying an indication of the new state.

Abstract: An example computer-implemented method embodying the disclosed technology comprises digitally storing a plurality of digital objects comprising first type digital objects and second type digital objects, each digital object comprising an electronic digital representation of natural language text, and certain first type digital objects each being associated with exactly one second type digital object; programmatically generating a corpus of digital documents from the plurality of digital objects; programmatically embedding the electronic digital representation of natural language text of each first type digital object not associated with one of the second type digital objects, thereby generating a second set of vectors; programmatically determining, for each of the second set of vectors, a corresponding set of nearest neighbor vectors from the first set of vectors; programmatically generating recommendation data indicating potential new associations between first type digital objects and second type digital ob

Abstract: In one embodiment, the disclosure provides a computer-implemented method comprising: generating a unique identifier associated with a digital electronic workspace, a project, a first account, and a second account; receiving, from the first account, input granting permissions to a second account; generating initial requirements data; receiving, a second input indicating a first set of one or more of the digital requirement objects to associate with the unique identifier; receiving, from the second account, a third input to generate and digitally store an additional digital requirement object and associating that object with the unique identifier; receiving input indicating consensus that the project should possess all the features described in natural language text summaries represented by the digital requirement objects; and changing a state value of a variable associated with the unique identifier to a new state and displaying an indication of the new state.

Abstract: An example computer-implemented method embodying the disclosed technology comprises digitally storing a plurality of digital objects comprising first type digital objects and second type digital objects, each digital object comprising an electronic digital representation of natural language text, and certain first type digital objects each being associated with exactly one second type digital object; programmatically generating a corpus of digital documents from the plurality of digital objects; programmatically embedding the electronic digital representation of natural language text of each first type digital object not associated with one of the second type digital objects, thereby generating a second set of vectors; programmatically determining, for each of the second set of vectors, a corresponding set of nearest neighbor vectors from the first set of vectors; programmatically generating recommendation data indicating potential new associations between first type digital objects and second type digital ob

Abstract: An example computer-implemented method embodying the disclosed technology comprises digitally storing a plurality of digital objects comprising first type digital objects and second type digital objects, each digital object comprising an electronic digital representation of natural language text, and certain first type digital objects each being associated with exactly one second type digital object; programmatically generating a corpus of digital documents from the plurality of digital objects; programmatically embedding the electronic digital representation of natural language text of each first type digital object not associated with one of the second type digital objects, thereby generating a second set of vectors; programmatically determining, for each of the second set of vectors, a corresponding set of nearest neighbor vectors from the first set of vectors; programmatically generating recommendation data indicating potential new associations between first type digital objects and second type digital ob

Abstract: Methods for CAD operations and corresponding systems and computer-readable mediums are disclosed herein. A method includes receiving 3D solid model data of a part to be manufactured, receiving at least one rule from a rules database, applying the rule to the 3D solid model data using a rules engine, and producing an output according the rule applied to the 3D solid model data. The rule can include an extraction portion which identifies elements or features of the 3D solid model data, a logic portion that applies a condition to the identified elements or features, and an action portion that defines an action to be performed to identified elements or features that meet the condition. The output can include an annotation of product manufacturing information to elements or features of the 3D solid model data that match the rule.

Abstract: Methods for computer aided design (CAD) and corresponding systems and computer-readable mediums. A method includes performing a setup process to instantiate a booklet of CAD drawings. The method includes receiving a user selection of a template from a user. The method includes receiving geometry content information from the user and receiving reference geometry from a user. The method includes creating the booklet of CAD drawings based on the template, geometry content information and reference geometry. A CAD system maintains a CAD drawing booklet, the CAD drawing booklet associated with a plurality of drawings each including a sheet collection, and each drawing associated with at least one component.

Abstract: Methods for product data management and corresponding systems and computer-readable mediums. A method includes displaying a user interface including at least one target object having a hover area. The method includes detecting that a user-controlled pointer is moved into the hover area and held in place for a first predetermined amount of time. The method includes displaying a dialog associated with the target object in response to the detecting. The method includes receiving configuration data from a user through the dialog and saving the received configuration data. The method can include receiving a selection of an access handle associated with the target object and, in response, activating the access handle and displaying at least one manipulation handle in the user interface.

Abstract: Methods for computer aided design (CAD) and corresponding systems and computer-readable mediums. A method includes performing a setup process to instantiate a booklet of CAD drawings. The method includes receiving a user selection of a template from a user. The method includes receiving geometry content information from the user and receiving reference geometry from a user. The method includes creating the booklet of CAD drawings based on the template, geometry content information and reference geometry. A CAD system maintains a CAD drawing booklet, the CAD drawing booklet associated with a plurality of drawings each including a sheet collection, and each drawing associated with at least one component.

Abstract: Substituted pyridin-2-ylamine analogues are provided, of the formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

Abstract: At least one chemical entity chosen from compounds of Formula 2 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

Abstract: Certain compounds, such as at least one chemical entity choen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, may in certain embodiments be used to treat patients suffering from one or more diseases responsive to inhibition of tyrosine kinase activity. The diseases may, for instance, be responsive to inhibition of Btk activity and/or B-cell proliferation. Example diseases include cancer, an autoimmune and/or inflammatory disease, and an acute inflammatory reaction.

Abstract: Chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are described herein. Pharmaceutical compositions comprising at least one chemical entity of Formula 1, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell proliferation are described. Methods for determining the presence of Btk in a sample are described.

Abstract: Substituted biphenyl-4-carboxylic acid arylamide analogues capable of modulating receptor activity, are provided. Such ligands may be used to modulate receptor activity in vivo or in vitro, and are particularly useful in the treatment of pain and other conditions associated with receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for receptor localization studies.

Abstract: Substituted spiro[isobenzofuran-1,4?-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4?-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

Abstract: At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, and prodrugs thereof. Methods of treating or preventing disorders in which aberrant kinase activity is implicated, pharmaceutically compositions, and methods for detecting the presence kinases in cells or biological preparations and for identifying kinases of therapeutic interest.

Abstract: Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.

Abstract: Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically-acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound of the invention to decrease the symptoms or slow the progression of these diseases or disorders.

Abstract: This invention pertains to compounds of Formula I: and the pharmaceutically-acceptable forms thereof. The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases.

Abstract: Substituted spiro[isobenzofuran-1,4?-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4?-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and method for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.